Drug Modeling Software Market, Drug Modeling Software Market Size, Drug Modeling Software Market Share, Drug Modeling Software
Insight Partners is adding “Drug Modeling Software Market Forecast to 2027 – Impact of Covid-19 and Global Analysis” to its store, providing an analysis of the current and future market competition in the market. Insightful overview of key market drivers, opportunities, barriers and challenges. Each trend is independently studied to provide a qualitative analysis of its impact.
Request sample pages of this research study at – https://www.theinsightpartners.com/sample/TIPRE00013619/?utm_source=OpenPR&utm_medium=10366
The drug modeling software market was valued at US$6,205.22 million in 2019 and is expected to reach US$11,299.85 million by 2027; It is expected to grow at a CAGR of 8.1% from 2020 to 2027.
Drug modeling has become an essential tool in the drug development process. Software-based drug discovery and development methods play a key role in the development of novel drugs. Software-based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered powerful tools to study pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate and provide valuable insight into experimental findings and mechanisms of action. In addition, proper implementation of these techniques can help reduce drug design and development costs. Increasing drug development costs coupled with increasing drug failures are expected to drive the growth of drug modeling software market over the forecast period. However, the market is likely to be negatively impacted by lower adoption of drug modeling software in emerging markets.
Order a copy of this research study at –
Product type based insights
Based on product type, drug modeling software market is segmented into database, software and other segments. The software segment had the largest market share in 2019. Successfully discovering, developing and bringing a single new drug to market costs approximately $1 billion and takes nearly 12 years. High cost, insufficient and long time duration, high risk, uncertainty in the results and highly complex procedures are the major challenges in developing a new drug. To overcome these problems, there is a strong need for new and cost-effective drug discovery and development methods, such as e.g. B. Software and computer-aided drug design and molecular docking. For example, the platform provided by Schrödinger has devoted decades to refining computational algorithms to accurately calculate the essential properties of molecules. The company uses NVIDIA GPUs to generate and analyze the petabytes of data to accelerate drug discovery, improving on the traditional process of slow and expensive lab work.
Exploring software and model-based tools has become an important avenue of drug discovery and development in the pharmaceutical industry, playing a crucial role in the dissemination of new bioactive drugs in a range of therapeutic areas. Proper use of software and computer-aided modern methods has broken down several obstacles in drug discovery and accelerated the development of new drugs.
Based on application, drug modeling software market is segmented into drug research and development, medical imaging, computational physiological medicine, predictive drug target analysis, disease modeling, simulation software, cell simulation, and others. The drug discovery process is complex and involves interdisciplinary efforts to develop practical and commercially viable drugs. In pharmaceutical, medical and other scientific research, a computer plays a significant role in developing new compounds in search of better therapeutics.
In addition, computing power together with advanced analytical techniques such as X-ray crystallography and NMR have improved the application of CADD (Computer-Aided Drug Design) in the field of pharmaceutical industry, such as numerous approved drugs that owe their discovery in large part to the tools of CADD, such as Angiotensin converting enzyme (ACE) inhibitor captopril, used to treat high blood pressure, carbonic anhydrase inhibitor dorzolamide, used to treat cystoid macular edema, renin inhibitor aliskiren, used for essential hypertension, human immunodeficiency virus (HIV) protease inhibitors saquinavir, Ritonavir and indinavir used to treat HIV. Additionally, the CADD and bioinformatics tools provide benefits such as cost savings, time-to-market, insight into drug-receptor interactions, and accelerate drug discovery and development. Such advantages that drug modeling software brings to drug research and drug development will drive the segment growth during the forecast period.
In addition, the development of new platforms offers other lucrative opportunities. For example, on March 16, 2020, Fujitsu partnered with Polarisqb to pilot a groundbreaking new drug discovery platform designed to help pharmaceutical companies bring essential medicines to market quickly and cost-effectively. The platform leverages quantum-inspired technology, machine learning, hybrid quantum mechanics and molecular mechanics simulation (QM/MM) to transform the drug discovery process. On July 19, 2019, Pumas-AI, a new company founded by faculty members from the University of Maryland School of Pharmacy, announced its first cutting-edge software platform for pharmaceutical researchers and clinicians, known as Pharmaceutical Modeling and Simulation (Pumas). It is a comprehensive platform based on the Julia programming language, containing several modules designed to meet the needs of analysts in the pharmaceutical industry while working to drive therapeutic innovation in the clinical setting. In August 2019, London, UK-based Evaluate, a company providing software services to researchers and drug developers, released Product Specific PTRS (Probability of Technical and Regulatory Success), a platform that processes data to predict a drug’s probability of success. However, the predictive drug target analysis segment is expected to witness significant growth rate during the forecast period
Prominent/Emerging Players in Drug Modeling Software Market Research include:
Avalon Health Economics LLC
The company overview provides information about the location of the company where it is headquartered, along with the year of incorporation, headcount as of 2017, the regions in which the company operates and key business areas.
Total company/segment revenue for 2019, 2018 and 2017 is presented in the sub-title Financial Performance (publicly traded companies) along with the analysis and explanation of the increase or decrease of the same due to factors such as merger and acquisition, profit or loss in a strategic business entity (sbus) and others.
The product benchmarking includes the comprehensive product list of each market along with its application and key features.
Insights into the company’s new product launches, strategic collaborations, mergers and acquisitions, regulatory approvals and other developments in the market are covered in the Strategic Initiatives section.
If you have any questions about this report or would like more information, please contact us:
North America: +1 646 491 9876
Asia Pacific: +91 20 6727 8686
Email: [email protected]
Insight Partners is a one-stop market research provider for actionable solutions. We help our clients find solutions to their research needs through our syndicated and consultative research services. We are specialists in industries such as Semiconductor & Electronics, Aerospace & Defense, Automotive & Transportation, Drug Modeling Software, Healthcare, Manufacturing & Engineering, Medical Devices, Technology, Media & Telecom, Chemicals & Materials.
Our research model is very simple. We believe in customer care and delivering the best quality to our customers. Through our research content, we ensure our clients get value for their money, along with better quality data and analysis.
Our research content mainly focuses on market trends in terms of market size, competitive landscape, company analysis, regional or country analysis, etc. We provide detailed breakdown of segmentation in terms of geography, technology, product & services, etc.; This helps our clients to get a deeper analysis on various research topics.
This version was published on openPR.